Skip to main content
Psychedelic State(s) of America
Subscribe
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Fresnobee

Published November 12, 2026

US to fund new research into psychedelic drug ibogaine for veterans with PTSD | Fresno Bee

Read the full story at Fresnobee

ketamine and psilocybin, expecting to name award winners in summer 2027. • ARPA-H will fund another ibogaine effort aimed at substance-use disorder.

Post on X

Share this story

Share on XShare on LinkedInShare on FacebookShare on WhatsAppShare on Signal

Surfaced by 4 Google Alerts

  • Ketamine
  • Ibogaine
  • Psychedelics
  • Psychedelic press release